Earth to Avacta, Earth to Avacta ...come in please. Oxygen levels low, the colony has been abandoned - to the TARDIS I say. News soon ( wink) Enjoy, get well positioned! |
Man U playing a Czech pornstar tonite?! Who the heck are they?! Entitled players, entitled club, badly run, no manager...not even the newbie. The guy can hardly speak English, never mind the Mancunian backwards language of the North West. Needs to come to the Queen.s English North East! Cough ,splutter ... |
Rinse, repeat ... quieter than a Man U 'fan'. Needs some value va voom. Death by a 1000 cuts. |
It's better to keep your mouth closed and let people think you're an idiot than to open your mouth and remove all doubt. Idiot! |
King Suarez another multi name poster returns. Canny timing I feel. |
That was a quick 6 months... |
Except Aman that everything forecast by the loons has happened.
The previous CEO fed out a heap load of BS, Myles assisted ignorant of risks and the extensive due diligence on the history of Ari6000 and 3996.
The lack of efficacy for uprated doses says it all. It’s clearly what Arisaph saw.
Flipped over to the AIM from the US via Avacta and now reality starting to bite.
LFTs a farce, Diagnostics company acquisition up for sale and to go phase 2 would be suicide, but obviously would drag out salaries for longer. |
Ohwhatfun lying merrily away. Board taken over by loons. |
"See you in 6 months or so".
Thanks. Now f#*CK off then and we'll see you again in the springtime |
Time has passed, pointing out the obvious drowned in blinkered hype investor posts.
Arisaph (Yes them) required materially increased efficacy and safety to progress to phase 2. They had seriously wealthy backers/co owner.
Efficacy here, has been woeful less than doxorubicin standard treatment. Clearly Arisaph saw the same and abandoned it. Obviously the method doesn’t work as hoped.
That on top of that chemo interest is backward looking. The pharma industry is chasing new highly efficacious therapies.
Avacta chasing archaic routes with a copycat known failure.
Spikes and drops on private investor surges and abandon ship.
See you in 6 months or so, to see low it is by then. |
If ever there was was comp for spinning a good ole yarn, GLA |
50p if your lucky.
Shorts from 74p more attractive?
Lev Sir, would advise stay away, this is another fools gold as with Nov.
cheers |
Very strong nosy buying today . 60p by day end ?? |
Q2 2025 Back for a punt? U missed it like the other ditherers. |
Looking like the quarter selling might have finished. |
Yes still around, I like to keep an eye on these lifestyle companies that fail to deliver anything but jam tomorrow stories. Pray tell, when does AVA6000 Phase 2 start? Sometime in 2024 they said, only 5 weeks left now. share price is still on a downward trend with the odd spike around payday loan conversion time. But hey dream on, tomorrow is another day. |
Stick with me Chesh ...nice little set up play complete. ££££££'s in. My hypothesis on the bent spine ups and downs is better than your glaring zero comment stuff. Funny how you appear again after a fall. Perhaps yourself and Raj might get a room? 2 blatant traders pretending not to be. Funny as. |
See yur still here 1347. The burk here and I trust you aren't still underwhelmed though it sounds like you could be. Maybe you could meet up with ama for solace as he's fretting over the convi boys. |
What's that got to do with Avacta? No-one's going to acquire Avacta out on the strength of one three year Phase 1a trial, all the other pipeline candidates having been quietly dropped, such that they've had to go back to the starting grid with two brand new ones. Hit the snooze button for another few years. |
Novartis have not finished acquiring and they are today upgrading their numbers again post another acquisition. |
 POLX FDA Approval received today big rise coming
POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.
Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval.
Massive takeover target and will be sold for 20p+ share price.
1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.
APPROX 13P SHARE PRICE EQUIVALENT FOR POLX
2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M
APPROX 48P SHARE PRICE EQUIVALENT FOR POLX
3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.
APPROX 22P SHARE PRICE EQUIVALENT FOR POLX
4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout
POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
